Q4 2017 Earnings Estimate for Merck & Company, Inc. (MRK) Issued By SunTrust Banks

Merck & Company, Inc. (NYSE:MRK) – Stock analysts at SunTrust Banks cut their Q4 2017 earnings estimates for shares of Merck & in a research note issued to investors on Sunday. SunTrust Banks analyst J. Boris now anticipates that the company will post earnings of $0.98 per share for the quarter, down from their previous estimate of $1.08. SunTrust Banks also issued estimates for Merck &’s FY2018 earnings at $4.12 EPS, FY2019 earnings at $4.44 EPS, FY2020 earnings at $4.92 EPS and FY2021 earnings at $5.52 EPS.

Merck & (NYSE:MRK) last released its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.14. The firm had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. Merck &’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.93 EPS.

WARNING: “Q4 2017 Earnings Estimate for Merck & Company, Inc. (MRK) Issued By SunTrust Banks” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/08/11/q4-2017-earnings-estimate-for-merck-company-inc-mrk-issued-by-suntrust-banks.html.

Several other research firms have also issued reports on MRK. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $74.00 price target (up from $70.00) on shares of Merck & in a research report on Thursday, July 27th. Citigroup Inc. set a $65.00 price target on shares of Merck & and gave the company a “hold” rating in a research report on Wednesday, July 5th. Zacks Investment Research upgraded shares of Merck & from a “hold” rating to a “buy” rating and set a $73.00 price target for the company in a research report on Friday, May 26th. BidaskClub lowered shares of Merck & from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. Finally, Piper Jaffray Companies set a $70.00 price target on shares of Merck & and gave the company a “buy” rating in a research report on Saturday, July 29th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $69.80.

Merck & (MRK) traded up 0.47% during trading on Wednesday, reaching $62.47. The company’s stock had a trading volume of 3,403,276 shares. Merck & has a 52-week low of $58.29 and a 52-week high of $66.80. The stock’s 50-day moving average is $63.46 and its 200 day moving average is $63.80. The firm has a market capitalization of $170.38 billion, a price-to-earnings ratio of 33.82 and a beta of 0.80.

The business also recently declared a quarterly dividend, which will be paid on Friday, October 6th. Investors of record on Friday, September 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s payout ratio is currently 76.11%.

A number of institutional investors have recently added to or reduced their stakes in MRK. PagnatoKarp Partners LLC increased its position in Merck & by 7.5% in the second quarter. PagnatoKarp Partners LLC now owns 9,263 shares of the company’s stock worth $598,000 after buying an additional 649 shares during the last quarter. D.A. Davidson & CO. increased its position in Merck & by 4.4% in the second quarter. D.A. Davidson & CO. now owns 443,191 shares of the company’s stock worth $28,404,000 after buying an additional 18,766 shares during the last quarter. Pinebridge Investments L.P. increased its position in Merck & by 12.3% in the second quarter. Pinebridge Investments L.P. now owns 500,502 shares of the company’s stock worth $32,077,000 after buying an additional 55,017 shares during the last quarter. GSA Capital Partners LLP increased its position in Merck & by 32.2% in the second quarter. GSA Capital Partners LLP now owns 14,784 shares of the company’s stock worth $948,000 after buying an additional 3,604 shares during the last quarter. Finally, Abbot Financial Management Inc. bought a new position in Merck & during the second quarter worth about $2,183,000. 73.73% of the stock is owned by institutional investors.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Earnings History and Estimates for Merck & (NYSE:MRK)

What are top analysts saying about Merck & Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Company Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit